You Position: Home > Paper
Splenic marginal zone lymphoma with lysine methyltransferase 2D gene mutation: report of 1 case and review of literature
( views:0, downloads:0 )
- Author:
- No author available
- Journal Title:
- Journal of Leukemia and Lymphoma
- Issue:
- 11
- DOI:
- 10.3760/cma.j.cn115356-20210809-00172
- Key Word:
- 脾边缘区淋巴瘤;赖氨酸甲基转移酶2D基因;抗肿瘤联合化疗方案;治疗;预后
Abstract： 目的:探讨伴赖氨酸甲基转移酶2D（KMT2D）基因突变脾边缘区淋巴瘤（SMZL）的临床表现和诊治过程。方法:回顾性分析2020年2月联勤保障部队第九四○医院收治的1例伴KMT2D基因突变SMZL患者的临床资料，并进行文献复习。结果:患者为25岁男性，给予CHOP方案后临床症状缓解不明显，后改为R-FC方案后缓解迅速，截至2021年8月患者为无症状生存。结论:KMT2D基因突变可能导致SMZL的发生，且伴KMT2D基因突变SMZL对CHOP方案不敏感，对含利妥昔单抗的联合化疗方案较为敏感。
- [1]中华医学会血液学分会.骨髓增生异常综合征中国诊断与治疗指南（2019年版）[J].2019,(2).
- [2]Fengling Min,Lijia Zhai,WEI ZHOU,etc.Two cases of chronic myelomonocytic leukemia combined with monoclonal gammopathy of undetermined significance and a literature review[J].2017,(1).
- [3]栗瑞敏,许玲,王菊美,等.骨髓增生异常综合征合并意义未明的单克隆免疫球蛋白血症1例诊治分析[J].2021,(1).
- [4]陈子兴.对成人和儿童骨髓增生异常综合征机制若干问题的新认识[J].2017,(9).
- [5]Yoshida,Y.,Oguma,S.,Ohno,H.,etc.Co-occurrence of monoclonal gammopathy and myelodysplasia: A retrospective study of fourteen cases[J].2014,99(6).
- [6]Premkumar Vikram J.,Lentzsch Suzanne,Pan Samuel,etc.Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis[J].2021,11(1).
- [7]Cazzola, Mario.Myelodysplastic Syndromes[J].2020,383(14).
- [8]Silverman LR,Demakos EP,Peterson BL,etc.Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.[J].2002,20(10).
- [9]Kurtin PJ,Hodnefield JM,Fonseca R,etc.Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma.[J].2007,356(25).
- [10]E Muchtar,A Dispenzieri,S K Kumar,etc.Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category[J].2016,31(7).
- [11]Oka, Satoko,Ono, Kazuo,Nohgawa, Masaharu.The effect of azacitidine therapy on the M protein of MDS patients with concomitant MGUS[J].2018,93(9).
- [12]Tilmann,Bochtler,Maximilian,Merz,Thomas,Hielscher,etc.Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma.[J].2018,2(20).
- [13]Sekeres MA.The epidemiology of myelodysplastic syndromes.[J].2010,24(2).
- [14]Armon Azizi,Asiri Ediriwickrema,Ritika Dutta,etc.Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience[J].2020,61(11).
- [15]van Nieuwenhuijzen, Niels,Spaan, Ingrid,Raymakers, Reinier,etc.From MGUS to Multiple Myeloma, a Paradigm for Clonal Evolution of Premalignant Cells[J].2018,78(10).
- [16]Touzeau, Cyrille,Maciag, Paulo,Amiot, Martine,etc.Targeting Bcl-2 for the treatment of multiple myeloma[J].2018,32(9).
- [17]刘红娟,宋丽君,包慎.骨髓增生异常综合征合并意义未明的单克隆免疫球蛋白血症一例并文献复习[J].2021,(2).
- [18]Roeker L E,Larson D R,Kyle R A,etc.Risk of acute leukemia and myelodysplastic syndromes in patients with monoclonal gammopathy of undetermined significance (MGUS): a population-based study of 17 315 patients[J].2013,27(6).